Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis

Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis

Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigat...

Full description

Bibliographic Details
Main Authors: Mobin Mohammadtabar, Alireza Fazeli, Najmeh Parsai, Zahra Aboulfathiyarmohammadyar, Erfan Shafiei, Mohamad Khaledi, Elahe Zaremoghadam, Ali Rahnama Sisakht, Saeid Mohammadi, Hossein Mardanparvar
Format: Article
Language:English
Published: Society of Diabetic Nephropathy Prevention 2023-03-01
Series:Journal of Nephropathology
Subjects:
cancer
neoplasm
diabetes
sglt2
sodium-glucose cotransporter-2
inhibitors
dapagliflozin
canagliflozin
empagliflozin
bladder
Online Access:https://nephropathol.com/PDF/jnp-12-e21444.pdf

Internet

https://nephropathol.com/PDF/jnp-12-e21444.pdf

Similar Items